It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Recent studies have revealed the importance of long noncoding RNAs (lncRNAs) as tissue-specific regulators of gene expression. There is ample evidence that distinct types of vasculature undergo tight transcriptional control to preserve their structure, identity, and functions. We determine a comprehensive map of lineage-specific lncRNAs in human dermal lymphatic and blood vascular endothelial cells (LECs and BECs), combining RNA-Seq and CAGE-Seq. Subsequent antisense oligonucleotide-knockdown transcriptomic profiling of two LEC- and two BEC-specific lncRNAs identifies LETR1 as a critical gatekeeper of the global LEC transcriptome. Deep RNA-DNA, RNA-protein interaction studies, and phenotype rescue analyses reveal that LETR1 is a nuclear trans-acting lncRNA modulating, via key epigenetic factors, the expression of essential target genes, including KLF4 and SEMA3C, governing the growth and migratory ability of LECs. Together, our study provides several lines of evidence supporting the intriguing concept that every cell type expresses precise lncRNA signatures to control lineage-specific regulatory programs.
Long noncoding RNAs regulate tissue-specific gene expression. Here the authors profile lineage-specific lncRNAs in human dermal lymphatic and blood vascular endothelial cells (LECs and BECs) and show a role of LEC-specific lncRNA, LETR1, in cell proliferation and migration.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Swiss Federal Institute of Technology and University of Zurich, Molecular Life Sciences PhD Program, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
2 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan (GRID:grid.5801.c); RIKEN Center for Life Science Technologies, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)
3 Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
4 Swiss Federal Institute of Technology (ETH) Zurich, Institute of Pharmaceutical Sciences, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780); Swiss Federal Institute of Technology and University of Zurich, Molecular and Translational Biomedicine PhD Program, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
5 RIKEN Center for Integrative Medical Sciences, Yokohama, Japan (GRID:grid.7597.c); RIKEN Center for Life Science Technologies, Yokohama, Japan (GRID:grid.7597.c) (ISNI:0000000094465255)